Aetna modified CPB 1068 for afamitresgene autoleucel (Tecelra), effective January 16, 2026. Here's what billing teams need to know before submitting claims.
Aetna, a CVS Health company, updated its Tecelra coverage policy under CPB 1068 Aetna system to clarify medical necessity criteria, precertification requirements, and site-of-care restrictions for this T-cell receptor therapy. The primary billing code is HCPCS Q2057, which covers afamitresgene autoleucel including leukapheresis and dose preparation per therapeutic dose. If your oncology or infusion billing team handles synovial sarcoma cases, this update directly affects your prior authorization workflow and claim submission process.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna, a CVS Health company |
| Policy | Afamitresgene Autoleucel (Tecelra) — CPB 1068 |
| Policy Code | CPB 1068 |
| Change Type | Modified |
| Effective Date | January 16, 2026 |
| Impact Level | High |
| Specialties Affected | Medical oncology, surgical oncology, infusion/chemotherapy administration, soft tissue sarcoma programs |
| Key Action | Verify all nine medical necessity criteria are met and precertification via NME (877-212-8811) is complete before billing Q2057 |
Aetna Afamitresgene Autoleucel Coverage Criteria and Medical Necessity Requirements 2026
The Aetna Tecelra coverage policy under CPB 1068 covers afamitresgene autoleucel as a one-time dose for adults with unresectable or metastatic synovial sarcoma. This is a narrow indication — nine criteria must all be satisfied before Aetna considers treatment medically necessary.
Here's what the policy requires, in full:
| # | Covered Indication |
|---|---|
| 1 | The member must have received prior chemotherapy treatment. |
| 2 | The tumor must test positive for one of these HLA alleles: HLA-A*02:01P, HLA-A*02:02P, HLA-A*02:03P, or HLA-A*02:06P. |
| 3 | The tumor must express the MAGE-A4 antigen. |
| 4 | The member must not have received Tecelra previously. |
| 5 | The member must not be heterozygous or homozygous for HLA-A*02:05P. |
| 6 | The member must have an ECOG performance status of 0 or 1. |
| 7 | The member must have adequate and stable cardiac and kidney function. |
| 8 | The member must not have received an allogeneic hematopoietic stem cell transplant. |
| 9 | The member must not have a clinically significant active infection or inflammatory disorder. |
Every single criterion must be met. Miss one, and you're looking at a claim denial for Q2057. That's not unusual for gene and cellular therapies, but the HLA typing requirements here are specific — HLA-A*02:05P heterozygosity or homozygosity is an absolute exclusion, even if every other criterion is satisfied.
This Aetna afamitresgene autoleucel coverage policy also classifies Tecelra as a Gene-based, Cellular & Other Innovative Therapies (GCIT®) product. That designation triggers dedicated review by Aetna's GCIT team and adds site-of-care requirements on top of the standard prior authorization process.
Precertification is mandatory. Contact Aetna's National Medical Excellence (NME) program at 877-212-8811. Do not treat this like a standard prior auth — NME handles GCIT products separately from routine precertification channels.
Site-of-care restrictions apply. Unless a member's health plan has opted out, Tecelra must be administered at an Aetna Institutes® GCIT Network designated center. Verify the treating facility is on the GCIT approved list before scheduling infusion. An out-of-network facility claim — even with a valid Q2057 authorization — will create reimbursement problems you don't want to untangle after the fact.
Aetna Afamitresgene Autoleucel Exclusions and Non-Covered Indications
Aetna's position here is direct: all indications other than unresectable or metastatic synovial sarcoma are experimental, investigational, or unproven.
There is no off-label coverage pathway described in CPB 1068. If a prescriber wants to use Tecelra for another sarcoma subtype or soft tissue malignancy, Aetna will not cover it under this policy. That's worth flagging to your clinical team early — off-label requests will not survive a medical necessity review under CPB 1068.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Unresectable or metastatic synovial sarcoma in adults ≥18 (all 9 criteria met) | Covered | Q2057, C49.0–C49.9, CPT 96413, CPT 96415 | One-time dose only; precertification via NME required; GCIT facility required |
| Synovial sarcoma — repeat dosing | Not Covered | Q2057 | Policy specifies one-time dose; continuation section refers only to dosage/administration |
| All other indications (any other cancer type, off-label use) | Experimental / Not Covered | — | Aetna considers all other uses investigational under CPB 1068 |
Aetna Tecelra Billing Guidelines and Action Items 2026
This therapy has a high administrative burden. A missed step in the precertification or eligibility process means a denied claim on a drug that costs hundreds of thousands of dollars. Work through this checklist before the effective date of January 16, 2026 applies to any pending cases.
| # | Action Item |
|---|---|
| 1 | Confirm GCIT facility status before scheduling. Check the Aetna Institutes® GCIT Designated Centers list for the treating facility. If your hospital or infusion center is not listed, your claim for Q2057 will not get paid regardless of medical necessity documentation. |
| 2 | Call NME at 877-212-8811 for precertification — not your standard PA line. This is a separate precertification channel for GCIT products. Routing a Tecelra request through standard prior authorization will delay approval or result in a process denial. |
| 3 | Document all nine medical necessity criteria in the precertification request. Pull the HLA typing results, MAGE-A4 antigen expression report, ECOG performance status, prior chemotherapy records, cardiac and kidney function labs, and transplant history. Missing documentation on any criterion gives Aetna grounds to deny or pend the request. |
| 4 | Bill Q2057 for the afamitresgene autoleucel infusion. This HCPCS code covers the drug, leukapheresis, and dose preparation procedures as a single per-therapeutic-dose billing unit. Pair it with CPT 96413 for the first hour of IV infusion and CPT 96415 for each additional hour. |
| 5 | Include CPT 80069 (renal function panel) in your charge capture if ordered. The medical necessity criteria require stable kidney function. Aetna lists 80069 as a related code under CPB 1068. If your team orders this panel as part of eligibility workup, bill it — it supports the medical necessity documentation trail. |
| 6 | Use the correct ICD-10-CM diagnosis code from C49.0–C49.9. Select the code that matches the anatomical site of the synovial sarcoma. All 10 codes in the C49 range map to synovial sarcoma under this policy. Don't default to C49.9 (unspecified) if you have site-specific documentation — payers notice. |
| 7 | Flag any member with a prior allogeneic stem cell transplant before submission. HCPCS S2142 and S2150 appear in CPB 1068 as related codes. Prior allogeneic transplant is a hard exclusion. If there's any transplant history, loop in your clinical team and compliance officer before submitting a precertification request. |
The real risk here isn't misunderstanding the criteria — it's skipping steps in a high-cost, high-scrutiny authorization process. One incomplete precertification packet on a six-figure therapy is a costly mistake. If your team is new to GCIT billing or hasn't handled a Tecelra case before, talk to your compliance officer or billing consultant before the January 16, 2026 effective date applies to live claims.
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Afamitresgene Autoleucel Under CPB 1068
HCPCS Codes — Covered When Selection Criteria Are Met
| Code | Type | Description |
|---|---|---|
| Q2057 | HCPCS | Afamitresgene autoleucel, including leukapheresis and dose preparation procedures, per therapeutic dose |
CPT and HCPCS Codes — Related to CPB 1068
These codes support workup, infusion administration, and related procedures referenced in the policy.
| Code | Type | Description |
|---|---|---|
| 96413 | CPT | Chemotherapy administration, IV infusion technique; up to 1 hour, single or initial substance/drug |
| 96415 | CPT | Chemotherapy administration, IV infusion; each additional hour (add-on to 96413) |
| 80069 | CPT | Renal function panel |
| S2142 | HCPCS | Cord blood-derived stem-cell transplantation, allogeneic |
| S2150 | HCPCS | Bone marrow or blood-derived stem cells (peripheral or umbilical), allogeneic or autologous, harvest |
Key ICD-10-CM Diagnosis Codes — Synovial Sarcoma
| Code | Description |
|---|---|
| C49.0 | Malignant neoplasm of connective and soft tissue — head, face, and neck |
| C49.1 | Malignant neoplasm of connective and soft tissue — upper limb, including shoulder |
| C49.2 | Malignant neoplasm of connective and soft tissue — lower limb, including hip |
| C49.3 | Malignant neoplasm of connective and soft tissue — thorax |
| C49.4 | Malignant neoplasm of connective and soft tissue — abdomen |
| C49.5 | Malignant neoplasm of connective and soft tissue — pelvis |
| C49.6 | Malignant neoplasm of connective and soft tissue — trunk, unspecified |
| C49.7 | Malignant neoplasm of connective and soft tissue — other specified sites |
| C49.8 | Malignant neoplasm of connective and soft tissue — overlapping sites |
| C49.9 | Malignant neoplasm of connective and soft tissue — unspecified site |
All 10 C49 codes are recognized under this coverage policy. Use the most specific anatomical code available in the member's record.
Get the Full Picture for CPT 96413
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.